The University of Oxford’s Vaccine Group has launched a Phase I trial testing safety and immune response in 50 healthy adults aged 18–55, as the Bundibugyo outbreak spreads across Congo and Uganda. As of July 11, Congo reported 1,926 cases and 702 deaths across five provinces; Uganda confirmed 20 cases and two deaths.

Oxford begins the world’s first human trial of a Bundibugyo Ebola vaccine
EURONEWS